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Over the past decade, the International AIDS Conference
has evolved from a purely scientific event into a reunion of
the international family of HIV researchers, policymakers
and care providers. The recent meeting in Bangkok boasted
a wide-ranging programme that attempted to cater for the
diverse interests of around 19 000 delegates. Achieving this
objective in the limited time available is a daunting
challenge for even the most skilled conference organiser.
This year it meant that delegates had to be satisfied with
small amounts of new information on a multitude of
topics.
The worldwide increase in the prevalence of antiretroviral
resistance is of particular concern to researchers and
practitioners. Since resistance remains one of the most
significant threats to the long-term success of any highly
active antiretroviral therapy (HAART) regimen, practitioners
are anxious to learn from past mistakes, translate new
knowledge into appropriate treatment strategies and
develop new drugs that retain useful activity in the face of
established resistance.
The conference programme emphasised three major areas
related to resistance: (i) concerns regarding non-nucleoside
reverse transcriptase inhibitors (NNRTIs), (ii) reassuring
data on certain protease inhibitors (PIs),  and (iii)
development of new agents with potential clinical utility
for treating resistant virus.
Considerable emphasis was placed on the selection of
resistant virus when using an NNRTI to prevent mother-to-
child transmission (MTCT) of HIV. Since nevirapine
(Viramune) is the current agent of choice in this setting, the
spotlight was brightly focused on this compound. It is
important to emphasise three important facts in this
regard. Most MTCT prevention strategies currently used in
resource-constrained environments employ regimens that
are known to have suboptimal virological efficacy. The
selection of NNRTI-resistant virus should therefore come as
no surprise. The consequences of suboptimal nevirapine
use are probably not unique to this agent, and are very
likely to emerge with the suboptimal use of any other
NNRTI.
Researchers from the conference’s host country1 presented
data on the emergence of resistance among Thai women
given zidovudine (AZT) monotherapy from the 28th week of
pregnancy followed by single-dose nevirapine during
labour. AZT resistance was subsequently documented in 5%
and NNRTI resistance in 41%. HIV subtype AE accounted for
the majority of infections; the G190A and the K103N
mutations were most commonly identified. G190A
mediates high-level phenotypic resistance to delavirdine
(Rescriptor) and nevirapine, whereas K103N confers high-
level phenotypic resistance to all currently available
NNRTIs.  Of interest was the high proportion of NNRTI-
resistant viruses (28%) with multiple resistance mutations.
Until recently, opinion has varied on the long-term
consequences of selecting NNRTI-resistant virus by single-
dose, or short-course MTCT interventions. Dr Marc
Lallement provided sobering information in this regard.2 He
described the outcome of HAART among 221 women who
had participated in the Thai Perinatal HIV Prevention Trial
(PHPT). All had previously received nevirapine and were
allocated to a regimen of stavudine (d4T), lamivudine (3TC)
and nevirapine. After 6 months of medication only 47%
had achieved full virological suppression (viral load
< 50 copies/ml). Thirty-two per cent of women had
nevirapine-resistant virus.
A novel strategy to avoid maternal exposure to nevirapine
might be administering the drug to the newborn as post-
exposure prophylaxis (PEP). Researchers from South Africa3
reported on the outcome of administering nevirapine as
PEP to 23 HIV-infected infants (PEP group); they compared
this with the outcome among 30 infants who were given
single-dose nevirapine at birth and whose mothers
received single-dose nevirapine during labour (standard
group). In the standard group, 11/30 (37%) of infants
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developed NNRTI resistance (all with the Y181C mutation
that causes high-level resistance to nevirapine and
delavirdine, and low-level resistance to efavirenz)
compared with only 3/23 (13%) in the PEP group. Curiously,
only the Y188C mutation (that mediates high-level
resistance to nevirapine and delavirdine) was found in the
latter group. These results require confirmation in larger
studies but suggest that innovative strategies for using
nevirapine in a non-HAART setting may result in
significantly lower rates of NNRTI resistance, perhaps with
different genotypic resistance profiles.
A final aspect of NNRTI resistance is the question of how
this phenomenon might affect the success of programmes
currently being rolled out in developing countries. HAART
regimens comprising AZT or d4T, plus 3TC, plus nevirapine
or efavirenz (Stocrin) are recommended as the preferred
first-line regimens in many guidelines. These combinations
are purported to be safe, effective and affordable, and are
often prescribed as fixed-dose, generic drug combinations.
The potential weakness of this approach is that both 3TC
and the NNRTIs have a low genetic barrier to resistance.
Data from our own centre4 documented a treatment failure
rate (viral load > 1 000 cp/ml) of over 20% within the first
12 months of therapy, despite apparently good treatment
adherence. Genotype analysis of these predominantly clade
C viruses showed that single-drug resistance was rare. Over
90% of patients failing therapy harboured virus with
resistance to multiple drugs including both nucleoside
reverse transcriptase inhibitors (NRTIs) and NNRTIs. Since a
patient’s initial HAART regimen is the one associated with
the greatest chance of treatment success, the universal use
of NNRTI-based regimens as first-line therapy warrants in-
depth evaluation and wider debate.
Lopinavir/ritonavir (Kaletra) received the lion’s share of the
scant information on this important topic. 
One of the benefits of PIs is their higher genetic barrier to
resistance. Long-term follow-up data on patients from
several sites in the USA5 confirmed the impressive
durability of treatment response to lopinavir/r and a
remarkably low rate of resistance among patients followed
up for over 5 years. Of an original group of 100 patients
enrolled in the 720 Study (stavudine, plus lamivudine, plus
lopinavir/r) 68 have remained on their allocated therapy for
a median of 5.4 years. Thirty-two have discontinued
therapy, 13 because of adverse events and 19 for other
reasons; none have stopped treatment because of
lopinavir/r resistance. Sixty-four of the 68 patients who
remain on treatment have viral loads < 50 copies/ml, 3
have viral loads of 50 - 400 copies/ml and only 1 has a viral
load of > 400 copies/ml. Resistance testing has confirmed
the presence of the M184V mutation in 3 of these
individuals (i.e. 3TC resistance). Minor mutations have been
documented in the protease gene sequence of 6
individuals. None of the mutations detected are recognised
as causing lopinavir resistance.
Because of the dominance of clade B virus in the developed
world, considerable attention has been devoted to studying
this subtype. Globally, however, the majority of HIV
infections occur in the developing world and these are due
to viruses belonging to other subtypes. Recently evidence
has emerged suggesting that resistance to certain
antiretroviral agents might evolve along different
pathways among clade B versus non-clade B virus. This is
particularly relevant to the clinical use of PIs.  Information
from Brazil6 added to the growing body of knowledge on
this important aspect of antiretroviral resistance. Subtype C
virus (which is also the most prevalent subtype in southern
Africa) frequently has a natural polymorphism at codon 93
in the protease gene known as I93L. This appears to render
the virus more susceptible to lopinavir/r.  In addition,
subtype C virus is unusual with regard to nelfinavir
(Viracept) resistance. Among clade B virus, nelfinavir
resistance is due to the selection of the D30N mutation;
this confers little cross-resistance to other PIs, permitting
the practitioner and patient to use PIs in a specific
sequence. For this reason, nelfinavir has been widely
advocated as the preferred initial PI in Europe, North
America and Australia. Clade C virus, however, is much
more likely to develop nelfinavir resistance via the L90M
mutation. In contrast to D30N, L90M mediates extensive
cross-resistance among the PIs. For treating clade C virus
nelfinavir is ranked equally with other, older unboosted PIs
with regard to its resistance profile.
A disappointing omission from the conference programme
was the lack of new data on the novel, once-daily PI
atazanavir (Reyetaz). Atazanavir has been approved for use
in many parts of the world. Registration in South Africa is
anticipated later this year, or early in 2005. In treatment-
naïve patients, atazanavir resistance has been associated
with a distinctive mutation known as I50L.  This confers no
cross-resistance to other PIs, suggesting that atazanavir
could have an important role as first-line PI therapy. To
date, however, clinical trial data suggest that atazanavir is
less potent than lopinavir/r. Many authorities therefore
recommend combining atazanavir with another PI such as
saquinavir, or boosting its pharmacological activity by the
concomitant administration of low-dose ritonavir.
Information is eagerly awaited on the impact that these
strategies will have on the evolution of PI resistance. 
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Data on two new agents, enfuvirtide and F-ddC, brought
bad news and good. Enfuvirtide (Fuzeon) is the first entry
inhibitor to enter general clinical use. Because of limited
manufacturing capacity and cost, enfuvirtide has generally
been reserved for treating patients with multi-drug-
resistant virus. Data from Canada showed that virus from
40 of 41 patients under treatment with this agent
developed a recognised enfuvirtide resistance mutation
after as little as 8 weeks of therapy. Several patients had
virus with multiple enfuvirtide mutations and/or novel
mutations affecting the drug’s site of action. This
disappointing information suggests that enfuvirtide may
be useful only when used as part of a maximally
suppressive HAART regimen. The current practice of
reserving its use for deep-salvage therapy may need to be
revised. By the time the next International Conference on
AIDS comes around, there should be early clinical data
available on the new oral fusion inhibitors, particularly the
novel CCR5-receptor blocker from Pfizer.
F-ddC (Reverset), a new cytidine analogue that inhibits
HIV-1 reverse transcriptase, was reported to be effective in
early phase II studies that recruited both treatment-naïve
and experienced patients.7 On average, viral loads dropped
by >1 log in the treatment-naïve group and 0.8 log in the
treatment-experienced group.  Larger studies have been
initiated in the USA and Europe. Preliminary results will be
released early next year. 
REFERENCES
1. Ngo-Giang-Huong N, Tungyai P, Kummee A, et al. Profile of NNRTI associated
mutations in women exposed to single dose of nevirapine during delivery in
Thailand. XV International Conference on AIDS, Bangkok,  11-16 July 2004 (WeOrB
1289).
2. Lallemant M. Drug resistance: challenge of antiretroviral therapy. XV International
Conference on AIDS, Bangkok, 11-16 July 2004 (Bridging Session — Hammer S and
Boucher C (moderators)).
3. Pillay C, Gray G, Chezzi C, et al. Nevirapine resistance mutations among HIV-1
infected infants following single-dose nevirapine. XV International Conference on
AIDS, Bangkok, 11-16 July 2004 (WeOrB 1290).
4. Miller S. Increasing global access to care. XV International Conference on AIDS,
Bangkok, 11-16 July 2004 (Symposium — Extending Antiretroviral Expertise).
5. Hicks C, da Silva B, Benson C, et al. Extensive resistance testing during five years of
lopinovir/ritonavir treatment in antiretroviral-naïve HIV-infected patients: results
from study M97-720. International Conference on AIDS, Bangkok, 11-16 July 2004
(WeOrB 1291).
6. Gonzalez-Olivieri, Brindeiro R, Soares M, et al. Impact of nelfinavir-resistance
mutations on Human Immunodeficiency Virus type 1 with subtype B and C
proteases. XV International Conference on AIDS, Bangkok, 11-16 July 2004 (We PeB
5704).
7. Murphy R, et al. Potent anti-HIV-1 activity of ReversetTM following 10 days of
monotherapy in treatment-naïve individuals. XV International Conference on AIDS,
Bangkok, 11-16 July 2004 (MoOrB 1056).
NEW AGENTS FOR TREATING RESISTANT HIV-1
To the Editor: In response to the overwhelming number of
patients presenting with oral lesions associated with HIV
infection at our local clinics and hospitals in KwaZulu-
Natal, a group of oral hygienists in the public sector have
developed a ‘mouth care pack’ initiative and flip chart
training guide.
As the hygienist’s scope of practice is limited the initiative
is very practical and can be implemented at any level of
care, from hospitals to home-based care.
Fundamentally the mouth care pack contains: a toothbrush
and toothpaste, bicarbonate of soda (to make a
mouthwash), chlorhexidine gluconate (0.2%) mint-
flavoured mouthwash, antibacterial soap, disposable cups,
and an instruction leaflet in English and Zulu.
An investigation at St Apollinaris Hospital, Centocow,
proved that a patient’s toothbrush is a vehicle for
transmission and re-infection of the mouth with many
bacterial and fungal conditions, particularly oral thrush.
Disinfecting the toothbrush with chlorhexidine, sodium
hypochlorite or antibacterial soap and correct storage are
most important in the management of patients’ oral health.
Packs are available for adults and children. The main
difference is in the size of the toothbrush, and packs are
packaged and dispensed by pharmacies. The packs have
been used very successfully, even for babies. The
mouthwash is applied using dental cotton wool rolls.
Fresh lemons are an adjunct to the treatment and lemon
water is offered to patients as part of their total oral health
care routine and to maintain hydration.
A power point and slide presentation have been completed
and our oral manifestations of HIV flip chart is being
produced and will be utilised in training and distributed to
all clinics within the province.
I would be pleased to offer further details.
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